A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction

Published:2018-08-31 Issue:8 Volume:37 Page:2810-2817
ISSN:0733-2467
Container-title:Neurourology and Urodynamics
language:en
Short-container-title:Neurourology and Urodynamics

Author:

Welk Blayne¹^ORCID,Hickling Duane²,McKibbon Mary³,Radomski Sidney⁴,Ethans Karen⁵

Affiliation:

1. Department of Surgery and Epidemiology and Biostatistics; Western University; London Ontario Canada

2. Department of Surgery; University of Ottawa; Ottawa Ontario Canada

3. St Josephs Hospital; London Ontario Canada

4. Department of Surgery; University of Toronto; Toronto Ontario Canada

5. Department of Medicine; University of Manitoba; Winnipeg Manitoba Canada

Funder

Astellas Pharma Canada

Rick Hansen Institute

Publisher

Wiley

Subject

Urology,Clinical Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/nau.23774/fullpdf

Reference31 articles.

1. EAU guidelines on neurogenic lower urinary tract dysfunction;Stöhrer;Eur Urol,2009

2. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis;Madhuvrata;Eur Urol,2012

3. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience;Wagg;BJU Int,2012

4. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database;Manack;Neurourol Urodyn,2011

5. Results of a randomized phase III trial of mirabegron in patients with overactive bladder;Nitti;J Urol,2013

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

2. Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study;Clinical Neuropharmacology;2024-05-14

3. Voiding Phase Dysfunction in Multiple Sclerosis;Urologic Clinics of North America;2024-05

4. An individual participant meta‐analysis of mirabegron in multiple sclerosis and spinal cord injury;Neurourology and Urodynamics;2024-03-13

5. Safety and efficacy of beta-3 adrenergic agonists in treating neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis;Investigative and Clinical Urology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3